Demant sees window of opportunity as millions lack hearing aids due to Covid-19

New products have driven Demant’s 2021 growth, but this was just the beginning. The Covid-19 pandemic has made the normally predictable hearing aid market unpredictable, but Demant wants to capitalize on the pent-up demand.

Søren Nielsen, Group CEO, Demant

For hearing aid manufacturers, 2020 and 2021 were like chalk and cheese.

This is demonstrated at Demant, which has just released its financial results for 2021, boasting its best-ever operating result.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs